NR5A2 (aka LRH-1) has been identified as a pancreatic cancer susceptibility gene with missing biological link. This study aims to demonstrate expression and potential role of NR5A2 in pancreatic cancer. NR5A2 expression was quantified in resected pancreatic ductal adenocarcinomas and the normal adjacent tissues of 134 patients by immunohistochemistry. The intensity and extent of NR5A2 staining was quantified and analyzed in association with overall survival (OS). The impact of NR5A2 knockdown on pancreatic cancer stem cell (CSC) properties and epithelial-mesenchymal transition (EMT) markers was examined in cancer cells using RT-PCR and Western Blot. NR5A2 was overexpressed in pancreatic tumors, the IHC-staining H score (mean ± SE) was 96.4 ± 8.3 in normal versus 137.9 ± 8.2 in tumor tissues (P < 0.0001).
tumor suppressor. 9 In the current study, we examined the expression of NR5A2 in tissues samples from PDAC patients in association with tumor characteristics and overall survival. We further investigated the possible molecular mechanisms that linking NR5A2 with PDAC.
Emerging evidence suggests that most solid tumors may arise from cancer stem cells (CSCs) and CSCs have been identified in pancreatic cancer. 10 can substitute for OCT4 in derivation of iPSCs and maintaining pluripotency. 12, 13 These observations suggest that NR5A2 may contribute to cancer development through a potential role in regulating CSCs. Yet, no study has addressed the effect of NR5A2
on pancreatic cancer cells from this perspective.
CSCs have also been linked to epithelial-to-mesenchymal transitions (EMT) in various solid tumors including PDAC. 14, 15 Cancer cells that undergo EMT and acquire stem cell-like features are believed to prelude metastasis. 16, 17 Indeed, circulating pancreatic cancer cells underwent EMT prior to dissemination in a genetically engineered mouse model. 18 Interestingly, NR5A2 has been linked to EMT in breast cancer and over-expression of NR5A2 promotes breast cancer motility and invasion by regulation of E-cadherin and MMP9 (matrix metallopeptidase 9). 19 Therefore, NR5A2 could be a key protein mediating properties shared by CSCs and EMT. The current study explored the role of NR5A2 in regulating CSC properties and EMT markers of pancreatic carcinoma cells.
| MATERIALS AND METHODS

| Cell lines and human tissues
Human pancreatic adenocarcinoma cell lines AsPC-1, PANC-1, MiaPaCa-2, Hs766T, and BxPC-3 cells were purchased from the American Type Culture Collection and cultured as described in their product information sheets. COLO357 and its fast growing (FG) were collected by centrifugation as described above.
| SiRNA Blocking
Small interfering RNA (siRNA) transfections were performed using , in which −ΔΔCt equals the ΔCt of the test group minus the ΔCt of the control group, which was normalized to one. 
| Western blotting
| Flow cytometry analysis
The CSC markers were measured by flow cytometry using the following FITC antibodies: mouse anti-human CD24 Clone ML5 (cat# 3 | RESULTS
| Expression of NR5A2 in pancreatic cancer cells and tumor tissues
Using quantitative RT-PCR analyses, we showed that NR5A2 mRNA was overexpressed in several pancreatic cancer cell lines (Fig. 1A) . The highest level of NR5A2 expression was detected in AsPC-1, followed by PANC-1, Hs766T, and MiaPaCa-2 cells. Western blot analysis showed consistency in the protein and mRNA expression levels, that is, a higher expression of NR5A2 protein in AsPC-1, PANC-1, and
Hs766T and MiaPaCa-2 cells (Fig. 1B) .
IHC analysis revealed that NR5A2 was overexpressed in pancreatic tumors compared to normal adjacent tissues (Fig. 2 , upper panels). Cytoplasmic and nuclear staining for NR5A2 was observed in 70.9% and 14.9% of the normal adjacent tissues and 88% and 3% of the tumor tissues, respectively (Supplementary Table 3 
| Characterization of CSCs in pancreatic cancer cell lines
To investigate the potential role of NR5A2 in pancreatic cancer, we conducted sphere formation assay and examined the impact of NR5A2 knock-down on CSC properties. We successfully obtained spheres in cell lines (AsPC-1 and PANC-1) that expressed higher levels of NR5A2 (Fig. 3A) . Importantly, spheres formed by AsPC-1 and PANC-1 could be serially passaged to form secondary (also referred as P2) and tertiary (P3) spheres (data not shown).
Using qRT-PCR method, we found a 1.30-12.83-fold higher mRNA levels of the transcription factors OCT4, NANOG, LIN28B (lin-28 homolog B), EED (embryonic ectoderm development), EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit), HEY1 (hes related family bHLH transcription factor with YRPW motif 1), SALL2 (spalt like transcription factor 2), SOX17 (SRY-box 17), and NR5A2 in sphere cells than in control adherent cells (Fig. 3B) . Western blot analysis also demonstrated a significantly higher level of protein expressions of CD44, Epcam, NANOG, OCT4, and NR5A2 in spheres compared with their corresponding adherent cells (Fig. 3C and D) .
Flow cytometry analysis showed a significantly increased expression of CSC markers in sphere-forming cells (Fig. 3E) . CD24 was expressed in 51.0 ± 0.03% (mean ± SD) of adherent and 92.5 ± 9.9%
sphere-forming AsPC-1 cells. knockdown reduced the number of sphere formation (Fig. 4A) .
The NR5A2 mRNA expression was inhibited by the two siRNAs by 76.07 ± 5.22% and 70.10 ± 7.10% in AsPC-1 CSCs, and 76.68 ± 4.36%
and 66.80 ± 3.82% in PANC-1 CSCs (Fig. 4B) . Consistently, Western blot analysis showed substantially reduced expression of NR5A2 protein in CSCs treated with specific siRNAs compared to that in cells treated with negative control siRNA (Fig. 4C) . Because siRNA1 showed a higher efficiency in inhibiting the NR5A2 expression than siRNA2, we chose the former for the following experiments.
| Knockdown of NR5A2 reduced the expression of pancreatic CSCs markers
Given the essential role of NR5A2 in sphere formation, we further tested the impact of NR5A2 knockdown on pancreatic CSC markers.
Using the qRT-PCR method, we found that NR5A2 knockdown significantly down-regulated the expression of CSC markers, such as transcription factors SOX2, NANOG, OCT4, and LIN28B ( Fig. 5A and B) .
Concomitantly, the expression of downstream targets of these transcription factors such as ZIC2 (Zic family member 2), ZIC3, SALL2 (spalt like transcription factor 2), and SALL4 were also significantly down-regulated ( Fig. 5A and B) . To further confirm the results, we have conducted Western blot analysis of selected genes.
Western blot analysis also demonstrated that the expressions of NANOG and OCT4 proteins were significantly lower in NR5A2-inhibited pancreatic CSCs compared with the control cells ( Fig. 5C and   D ). Polycomb group proteins are known to be involved in the regulation of gene repression through chromatin modifications, which is essential for the maintenance of the embryonic and adult stem cells. 22 Polycomb repressive complex 2 (PRC2) contains EED, EZH2, and SUZ12 (SUZ12 polycomb repressive complex 2 subunit) subunits and functions in the embryonic and adult stem cells to repress developmental genes that are preferentially activated during differentiation. 23 In our experiments, we found that the expression levels of EED, EZH2, and SUZ12 mRNA were decreased in NR5A2-inhibited pancreatic CSCs compared with the control (Fig. 5A and B) . Western blot also confirmed reduced expression of EZH2 protein in these cells ( Fig. 5C and D) . (Fig. 5A and B) . Likewise, Western blot analysis as shown in Figure 5C and D confirmed the lower protein expression of NOTCH1 in NR5A2-knockdown cells. proteins such as metalloproteinases (MMP) 2, 3, and 9, which are involved in basement membrane degradation, are also over expressed during EMT. 24, 25 To determine whether NR5A2 could affect EMT in pancreatic cancer, we next examined the expression of epithelial and mesenchymal marker in NR5A2-inhibited pancreatic CSCs. We found that NR5A2
knockdown suppressed mRNA expression of FGB (fibrinogen β chain), FN1 (fibronectin 1), MMP2, MMP3, MMP9, TWIST (twist family bHLH transcription factor 1), SNAIL (snail family transcriptional repressor 1), ZEB1 (zinc finger E-box binding homeobox 1), but not ZEB2 (Fig. 6A and   B) . At the protein level, NR5A2 knockdown increased the expression of E-cadherin and total β-catenin but decreased expression of vimentin ( Fig. 6C and D) . Furthermore, the increased expression of β-catenin was confirmed by flow cytometry (Fig. 6E and F) . These data suggested that silencing of the NR5A2 gene may negatively modulates EMT process, and has the potential to reverse the EMT in pancreatic CSCs.
| DISCUSSION
In this study, we have shown that NR5A2 gene is overexpressed in pancreatic cancer cell lines and in human PDAC tumor tissues NR5A2 has been identified as a susceptibility gene for pancreatic cancer. 1 However, the biological function of NR5A2 in pancreatic cancer is not clear. Studies in animal models reported controversial roles of NR5A2 as an oncogene. 24 or a tumor suppressor gene 9 in pancreatic cancer. NR5A2 was overexpressed in human pancreatic cancer cell lines and in human pancreatic tumor tissues. 7 The current study has further demonstrated in a tissue array of 134 resected PDAC tumor samples that overexpression of NR5A2 was associated with significantly reduced survival and increased risk of death in PDAC patients. This finding provides supporting evidence that NR5A2 may play an oncogenic role in pancreatic cancer. Although no significant association between NR5A2 expression and tumor characteristics was observed, tumor tissues showed a significantly lower proportion of nuclear staining than that of the normal adjacent tissues. The biological significance of the cellular localization of this protein needs further investigation.
The mechanisms of NR5A2-related pancreatic carcinogenesis may involve proliferation of dedifferentiated pancreatic cancer cells and the reprogramming events in the adult pancreas that lead to its transformation. 7 In vitro experiments have shown that knockdown of EMT is an important process contributing to the invasion, metastasis, chemo-resistance, 16, 27, 28 and the propagation of cancer stem cells 14, 15 in solid tumors including pancreatic cancer. [29] [30] [31] The EMT process is associated with loss of epithelial dedifferentiation and switching toward mesenchymal phenotype, thus decreased expression of epithelial markers such as E-cadherin and increased expression of mesenchymal markers such vimentin. In the current study, we found that in pancreatic CSCs transfected with NR5A2 siRNA, epithelial markers (E-Cadherin) was highly over expressed whereas mesenchymal markers vimentin was under expressed at both the RNA and protein levels (Fig. 6) . Furthermore, the increased expression of E-Cadherin coincided with the reduced expression of mesenchymal markers such as the members of the SAIL/SLUG family of zinc-finger transcription factors as well proteins that are involved in basement membrane degradation (Fig. 6 ). Consistent with our findings, a previous study had shown that NR5A2 co-activates nuclear β-catenin/Tcf4 to promote intestinal cell proliferation by stimulating the expression of the G1 cyclins D1 and E1. 4 In addition, NR5A2
promoted the motility and invasiveness of breast cancer, which was associated with decreased E-cadherin mRNA expression, the post-translation cleavage of mature 120 kDa E-Cadherin to its inactive 97 kDa form, as well as induced MMP9 mRNA expression. 19 All these experimental evidence support a role of NR5A2 in promoting EMT.
On the other hand, NR5A2 silencing has the potential to reverse the EMT in pancreatic cancer cells. 8 The current study has demonstrated that NR5A2 knockdown in pancreatic CSCs increased the expression of E-Cadherin (as shown by Western blot) and β-catenin (as shown by both Western blot and flow cytometry).
Although an inverse correlation between E-cadherin and Wnt/β-catenin signaling has been reported in other studies, 32, 33 increased level of total β-catenin, which was attributable to an increase in the E-cadherin-associated membrane fraction of β-catenin has been associated with differentiation in colon cancer cells. 34 We used wholecell lysate not nuclear extracts in the Western blot assay, which FIGURE 6 NR5A2 regulates EMT-related marker genes in pancreatic CSCs. Panel A and B showed decreased mRNA expression of EMTrelated transcription factor such as FGB, FN1, MMP2, MMP3, MMP9, TWIST, SNAIL, and ZEB1 and the mesenchymal marker Vimentin, and increased expression of the epithelial marker E-cadherin in NR5A2-inhibited PANC-1 and AsPC-1 CSCs compared with controls. Relative mRNA levels were normalized to GAPDH. Panel C and D showed reduced protein expression of the mesenchymal marker Vimentin and increased expression of the epithelial marker E-cadherin and β-catenin in NR5A2-inhibited PANC-1 and AsPC-1 CSCs compared with controls. Expression of β-actin was used as an internal control. Panel E showed the increased expression of membrane β-catenin in NR5A2-inhibited AsPC-1 sphere-forming cells compared to that in control siRNA-transfected cells by flow cytometry measured the total β-catenin. The flow cytometry analysis showed a high level of membrane-associated β-catenin. These data suggest that silencing of NR5A2 may play a role in inducing cell differentiation, enhancing cell-cell adhesion and suppressing EMT. 35 In summary, we have shown that NR5A2 is overexpressed in human pancreatic adenocarcinoma and the overexpression of NR5A2
was associated with significantly reduced survival and increased risk of death. Using the in vitro sphere formation assay, we have shown an enrichment of NR5A2 in pancreatic CSCs, and the expression levels of NR5A2 and its transcriptional targets correlated with pancreatic CSCs' sphere formation. Considering that sphere-generating cells are highly aggressive in vivo when compared with adherent cells, 36 our data suggest that NR5A2 might be a functional pancreatic CSC marker.
Findings from NR5A2-inhibition experiments suggest a possible role of NR5A2 in maintaining CSC properties and in EMT. Further investigations are necessary to corroborate these preliminary but interesting findings and to better understand the role of NR5A2 in pancreatic carcinogenesis.
